Berlex To Launch Menostar As Lowest Dose Estrogen Patch Approved For Osteoporosis Prevention
This article was originally published in The Pink Sheet Daily
Executive Summary
Low estrogen dose reduces need for concomitant progestin therapy in women who have a uterus. Berlex will study longer-term use following June 8 FDA approval.